AMENDMENTS TO THE CLAIMS

Claims 4-6, 14-19, and 22-25 are amended herein. Claims 27-29 is newly added herein. Support for the amendments can be found throughout the specification and claims as originally filed. Claims 13, and 20-21 are cancelled herein. Claims 1-3 were previously cancelled. Claims 7-10 were previously withdrawn from consideration. This listing of claims will replace all prior versions, and listings of claims, in the application.

Listing of Claims:

1-3. (Cancelled)

4. (Currently Amended) A pharmaceutical composition comprising:

(a) a ~~pharmaceutically acceptable carrier and a safe and~~ therapeutically-effective amount of the compound of formula I or ~~the~~ a pharmaceutically acceptable salts thereof, wherein



Formula (I)

R_1 is methyl, ethyl or trifluoromethyl at position 3, 4, 5 or 6;

R_2 is hydroxyl, sulfydryl, methylthio group, or ethylthio group at position 2, 3 or 4; and

(b) a pharmaceutically-acceptable excipient.

5. (Currently Amended) The pharmaceutical composition according to claim 4, wherein the composition comprises ~~comprising~~ 0.01-99% of the compound of formula I or the pharmaceutically acceptable salts thereof, on the basis of the total weight.

6. (Currently Amended) ~~A~~ The pharmaceutical composition according to claim 4, wherein the ~~dosage form of the pharmaceutical~~ composition is formulated as a tablet, capsule, ampule or pill.

7. (Withdrawn) A method for producing the compound of formula I, comprising the steps of:

(a) in the presence of copper powder and anhydrous alkaline earth metal carbonate, reacting the compound of formula II and the compound of formula III at 160-200° C., thereby producing the compound of formula Ia;



wherein

R_1 is methyl, ethyl or trifluoromethyl at position 3, 4, 5 or 6,

R_3 is --OCH_3, --SCH_3, --OC_2H_5 or --SC_2H_5 at position 2, 3 or 4, and

X is Cl, Br or I;

(b) reacting the compound of formula Ia and BBr_3 in an inert solvent at -10° C. to 15° C., thereby producing the compound of formula I:



wherein, R_1 and R_3 are defined as above, and R_2 is -OH or -SH.

8. (Withdrawn) A method for producing a pharmaceutical composition, comprising the steps of mixing the compound of formula I or the pharmaceutically acceptable salts thereof according to claim 1 with a pharmaceutically acceptable carrier to produce a pharmaceutical composition comprising 0.01-99 wt % of the compound of formula I, on the basis of the total weight.

9. (Withdrawn) Use of the compound of formula I or the pharmaceutically acceptable salts thereof according to claim 1 in the manufacture of a medicament for preventing fibrosis.

10. (Withdrawn) A method for treating fibrosis diseases, comprising administrating a safe and effective amount of the compound of formula I or the pharmaceutically acceptable salts thereof according to claim 1 to a subject in need thereof.

11. (Previously Presented) The pharmaceutical composition according to claim 4, wherein R_1 is methyl, and R_2 is hydroxyl.

12. (Previously Presented) The pharmaceutical composition according to claim 4, wherein R_1 is methyl at position 5, and R_2 is hydroxyl at position 4.

13. (Cancelled)

14. (Currently Amended) The pharmaceutical composition according to claim 4, wherein the pharmaceutical composition is formulated for oral, intravenous, intramuscular or subcutaneous administration ~~administered orally, intravenously, intramuscularly or subcutaneously~~.

15. (Currently Amended) The pharmaceutical composition according to claim 4, wherein the pharmaceutical composition is formulated for oral administration ~~orally administered~~.

16. (Currently Amended) The pharmaceutical composition according to claim 4, wherein the pharmaceutical composition is formulated for external administration ~~administered by external use~~.

17. (Currently Amended) The pharmaceutical composition according to claim ~~15~~ 4, wherein the ~~dosage form of the pharmaceutical~~ composition is formulated as an ointment, gel, or drug-containing rubber cement.

18. (Currently Amended) The pharmaceutical composition according to claim 4, wherein the pharmaceutical composition is formulated for parenteral administration ~~administered parenterally~~.

19. (Currently Amended) The pharmaceutical composition according to claim 4, wherein the composition comprises ~~comprising~~ 0.1-90% of the compound of formula I or the pharmaceutically acceptable salts thereof, on the basis of the total weight.

20-21. (Cancelled)

22. (Currently Amended) The pharmaceutical composition according to claim 4, wherein the pharmaceutical composition ~~is administered in~~ is formulated for ~~2-4 separated dosages per day, or in the form of~~ slow release.

23. (Currently Amended) The pharmaceutical composition according to claim ~~13~~ 4, wherein ~~said carrier~~ the excipient is ~~comprises a solid carrier selected from the group consisting of~~ starch, lactin, dicalcium phosphate, microcrystalline cellulose, sucrose, ~~and~~ white bole or combinations thereof.

24. (Currently Amended) The pharmaceutical composition according to claim ~~13~~ 4, wherein ~~said carrier~~ the excipient is ~~comprises a liquid carrier selected from the group consisting of~~ sterile water, polyethylene glycol, a nonionic surfactant, ~~and~~ edible oil or combinations thereof.

25. (Currently Amended) The pharmaceutical composition according to claim 4, ~~wherein the pharmaceutical composition comprises~~ further comprising an adjuvant ~~selected from the group consisting of a flavoring agent, colorant, preservative, and antioxidant such as vitamin E, vitamin C, BHT and BHA~~.

27. (New) The pharmaceutical composition according to claim 4, wherein the pharmaceutical composition is formulated for administration in 2-4 separated dosages per day.

28. (New) The pharmaceutical composition according to claim 4, further comprising a flavoring agent, colorant, preservative, antioxidant, or combinations thereof.

29. (New) The pharmaceutical composition according to claim 4, further comprising vitamin E, vitamin C, BHT and BHA or combinations thereof.